Background: Patients (pts) with refractory chronic cough (RCC) are often treated for underlying
conditions commonly associated with cough.
Aim: To evaluate treatments used over time for suspected causes of cough in RCC.
Methods: SOOTHE (NCT04678206) was a randomised, multi-centre, double-blind, placebo-controlled,
parallel arm, dose-finding study of camlipixant for RCC treatment. This post-hoc analysis
evaluated self-reported and investigator-recorded prior and concomitant medication
(CM) use.
Results: Of the 310 pts with RCC, 73.2, 75.5 and 69.4% reported prior treatment and 31.6,
36.5 and 28.4% reported CM at screening for asthma, gastro-oesophageal reflux disease
(GERD) and upper airway cough syndrome (UACS), respectively. Of the pts who reported
prior treatment for asthma, GERD and UACS, most reported no symptom improvement ([Fig. 1]); this was similar between genders. Numerically more males vs females reported asthma
CM at screening. The proportion of pts who reported prior treatment and CM for asthma
or UACS was similar for pts<65 vs≥65 yrs, but numerically more pts≥65 yrs reported
prior treatment and CM for GERD. More pts<65 yrs reported no improvement with prior
antileukotriene treatment vs≥65 yrs.
Conclusions: Despite CM use for underlying conditions, pts had inadequate control of their cough,
largely unrelated to age or gender.
Fig. 1
Encore statement: This abstract was originally presented as poster PA319 at the European Respiratory
Society (ERS) Meeting on September 8, 2024, this encore is presented on behalf of
the original authors with their permission.
Disclosures: This study was sponsored by Bellus Health, a GSK company. Medical editing support
for the development of this abstract, under the direction of the authors, was provided
by Ciara Mulhern, BSc, of Ashfield MedComms, an Inizio company, and funded by GSK.
